Anika Therapeutics, Inc.ANIKNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank43
3Y CAGR+36.4%
5Y CAGR-3.1%
Year-over-Year Change
Cash generated from core business operations
3Y CAGR
+36.4%/yr
vs -40.4%/yr prior
5Y CAGR
-3.1%/yr
Recent acceleration
Acceleration
+76.8pp
Accelerating
Percentile
P43
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
2 yr
Consecutive growthContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $11.19M | +107.1% |
| 2024 | $5.40M | +402.2% |
| 2023 | $-1.79M | -140.6% |
| 2022 | $4.41M | -47.5% |
| 2021 | $8.40M | -35.7% |
| 2020 | $13.06M | -64.7% |
| 2019 | $37.01M | +6.0% |
| 2018 | $34.92M | -14.4% |
| 2017 | $40.81M | +71.5% |
| 2016 | $23.80M | - |